A5037998532- Diabetes Management and Research
- Diabetes and associated disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pancreatic function and diabetes
- Scientific Computing and Data Management
- Diabetes Treatment and Management
- Statistical Methods in Clinical Trials
- Radioactive Decay and Measurement Techniques
- Biomedical Text Mining and Ontologies
- Clinical Laboratory Practices and Quality Control
Alder Hey Children's NHS Foundation Trust
2013-2023
To compare the efficacy, safety, and cost utility of continuous subcutaneous insulin infusion (CSII) with multiple daily injection (MDI) regimens during first year following diagnosis type 1 diabetes in children young people.Pragmatic, multicentre, open label, parallel group, randomised controlled trial economic evaluation.15 paediatric National Health Service (NHS) services England Wales. The study opened to recruitment May 2011 closed January 2017.Patients aged between 7 months 15 years, a...
We evaluated the use of hybrid closed-loop (HCL) insulin delivery with faster aspart (Fiasp) in very young children type 1 diabetes (T1D). In a double-blind, multicenter, randomized, crossover study, aged 2–6 years T1D underwent two 8-week periods HCL using CamAPS FX Fiasp and standard (IAsp), random order. Primary endpoint was between-treatment difference time target range 3.9–10.0 mmol/L. randomized 25 participants: mean (±standard deviation) age 5.1 ± 1.3 years, baseline HbA1c 55 9...
We evaluated the effect of long-term intensive metabolic control with hybrid closed-loop (CL) on residual C-peptide secretion and glucose compared standard insulin therapy in youth type 1 diabetes over 48 months.
The risk of developing long-term complications type 1 diabetes (T1D) is related to glycaemic control and reduced by the use intensive insulin treatment regimens: multiple daily injections (MDI) (≥ 4) continuous subcutaneous infusion (CSII). Despite a lack evidence that more expensive with CSII superior MDI, both treatments are used widely within NHS. (1) To compare during MDI (2) determine safety cost-effectiveness treatment, quality life (QoL) patients. A pragmatic, open-label randomised...
Intensive insulin therapy with continuous subcutaneous infusion (CSII) devices or multiple daily injections (MDI) reduces the risk of long-term vascular complications type I diabetes (TID). Both treatments are used routinely, but there is little evidence to demonstrate superiority either treatment. If CSII treatment associated an improved quality life (QoL), additional cost this may be compensated for by a reduction in health expenditure. no demonstrable difference between treatments,...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)